Presentation is loading. Please wait.

Presentation is loading. Please wait.

Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent.

Published byМиљенко Марјановић Modified over 6 years ago

Similar presentations

Presentation on theme: "Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent."— Presentation transcript:

1 Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy  Domenico Galetta, MD, Alfredo Cesario, MD, Stefano Margaritora, MD, Venanzio Porziella, MD, Alessio Piraino, MD, Rolando M. D’Angelillo, MD, Maria A. Gambacorta, MD, Sara Ramella, MD, Lucio Trodella, MD, Salvatore Valente, Giuseppe M. Corbo, Giuseppe Macis, Antonino Mulè, Vittorio Cardaci, MD, Silvia Sterzi, MD, Pierluigi Granone, MD, Patrizia Russo, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 131, Issue 2, Pages e3 (February 2006) DOI: /j.jtcvs Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

2 Figure E1 Treatment plan. GEM, Gemcitabine.
The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

3 Figure E2 Survival curve of all eligible patients. Numbers at bottom indicate patients at risk. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

4 Figure E3 Survival curves for patients with resected (R, solid line) versus nonresected (NR, dotted line) disease. Numbers at bottom indicate patients at risk. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

5 Figure E4 Disease-free survival among patients undergoing resection. Numbers at bottom indicate patients at risk. The Journal of Thoracic and Cardiovascular Surgery  , e3DOI: ( /j.jtcvs ) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent."

Similar presentations

Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma  Rebecca P. Petersen, MD, MSc, Steven.

Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma  Rebecca P. Petersen, MD, MSc, Steven.
The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,
Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: A multicenter comparative trial 

Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: A multicenter comparative trial 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,

Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis  Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.

Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis  Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.
Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer  Marco Alifano, MD, PhD, Pierre.

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer  Marco Alifano, MD, PhD, Pierre.
Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series  Filippo Lococo, MD, Alfredo Cesario, MD, Giuseppe Cardillo,

Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series  Filippo Lococo, MD, Alfredo Cesario, MD, Giuseppe Cardillo,
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.
Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study  Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study  Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

Similar presentations

Ads by Google